vs
碧迪（BDX）与PACS Group, Inc.（PACS）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是PACS Group, Inc.的3.9倍（$5.3B vs $1.4B）。碧迪净利率更高（7.3% vs 4.4%，领先2.9%）。PACS Group, Inc.同比增速更快（18.4% vs -0.4%）。过去两年PACS Group, Inc.的营收复合增速更高（20.5% vs 2.0%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
BDX vs PACS — 直观对比
营收规模更大
BDX
是对方的3.9倍
$1.4B
营收增速更快
PACS
高出18.8%
-0.4%
净利率更高
BDX
高出2.9%
4.4%
两年增速更快
PACS
近两年复合增速
2.0%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $1.4B |
| 净利润 | $382.0M | $59.7M |
| 毛利率 | 45.9% | — |
| 营业利润率 | 10.5% | 7.0% |
| 净利率 | 7.3% | 4.4% |
| 营收同比 | -0.4% | 18.4% |
| 净利润同比 | 24.0% | 3022.5% |
| 每股收益（稀释后） | $1.34 | $0.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXPACS
| Q4 25 | $5.3B | $1.4B | ||
| Q3 25 | $5.9B | $1.3B | ||
| Q2 25 | $5.5B | $1.3B | ||
| Q1 25 | $5.3B | $1.3B | ||
| Q4 24 | $5.2B | $1.1B | ||
| Q3 24 | $5.4B | $1.0B | ||
| Q2 24 | $5.0B | $981.4M | ||
| Q1 24 | $5.0B | $934.3M |
净利润BDXPACS
| Q4 25 | $382.0M | $59.7M | ||
| Q3 25 | $493.0M | $52.4M | ||
| Q2 25 | $574.0M | $51.0M | ||
| Q1 25 | $308.0M | $28.5M | ||
| Q4 24 | $303.0M | $1.9M | ||
| Q3 24 | $400.0M | $15.6M | ||
| Q2 24 | $487.0M | $-10.9M | ||
| Q1 24 | $537.0M | $49.1M |
毛利率BDXPACS
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 47.8% | — | ||
| Q1 25 | 42.8% | — | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | 17.1% | ||
| Q2 24 | 46.2% | 22.3% | ||
| Q1 24 | 45.7% | 21.2% |
营业利润率BDXPACS
| Q4 25 | 10.5% | 7.0% | ||
| Q3 25 | 11.8% | 6.4% | ||
| Q2 25 | 16.0% | 6.2% | ||
| Q1 25 | 10.4% | 3.8% | ||
| Q4 24 | 8.8% | 1.7% | ||
| Q3 24 | 11.4% | 2.2% | ||
| Q2 24 | 12.1% | 0.1% | ||
| Q1 24 | 14.5% | 8.6% |
净利率BDXPACS
| Q4 25 | 7.3% | 4.4% | ||
| Q3 25 | 8.4% | 3.9% | ||
| Q2 25 | 10.4% | 3.9% | ||
| Q1 25 | 5.8% | 2.2% | ||
| Q4 24 | 5.9% | 0.2% | ||
| Q3 24 | 7.4% | 1.5% | ||
| Q2 24 | 9.8% | -1.1% | ||
| Q1 24 | 10.6% | 5.3% |
每股收益（稀释后）BDXPACS
| Q4 25 | $1.34 | $0.42 | ||
| Q3 25 | $1.71 | $0.32 | ||
| Q2 25 | $2.00 | $0.31 | ||
| Q1 25 | $1.07 | $0.17 | ||
| Q4 24 | $1.04 | $-0.03 | ||
| Q3 24 | $1.37 | $0.10 | ||
| Q2 24 | $1.68 | $-0.07 | ||
| Q1 24 | $1.85 | $0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $197.0M |
| 总债务越低越好 | — | $353.2M |
| 股东权益账面价值 | $25.3B | $946.8M |
| 总资产 | $54.8B | $5.6B |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资BDXPACS
| Q4 25 | $740.0M | $197.0M | ||
| Q3 25 | $641.0M | $355.7M | ||
| Q2 25 | $735.0M | $294.2M | ||
| Q1 25 | $667.0M | $287.5M | ||
| Q4 24 | $711.0M | $157.7M | ||
| Q3 24 | $1.7B | $49.5M | ||
| Q2 24 | $4.5B | $73.4M | ||
| Q1 24 | $2.3B | $81.2M |
总债务BDXPACS
| Q4 25 | — | $353.2M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $411.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BDXPACS
| Q4 25 | $25.3B | $946.8M | ||
| Q3 25 | $25.4B | $871.3M | ||
| Q2 25 | $25.5B | $806.8M | ||
| Q1 25 | $25.2B | $750.2M | ||
| Q4 24 | $25.2B | $709.6M | ||
| Q3 24 | $25.9B | $660.0M | ||
| Q2 24 | $25.9B | $572.1M | ||
| Q1 24 | $25.6B | $128.0M |
总资产BDXPACS
| Q4 25 | $54.8B | $5.6B | ||
| Q3 25 | $55.3B | $5.6B | ||
| Q2 25 | $54.9B | $5.5B | ||
| Q1 25 | $54.5B | $5.5B | ||
| Q4 24 | $54.7B | $5.2B | ||
| Q3 24 | $57.3B | $4.5B | ||
| Q2 24 | $55.6B | $3.9B | ||
| Q1 24 | $54.2B | $3.9B |
负债/权益比BDXPACS
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.58× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $-3.4M |
| 自由现金流经营现金流 - 资本支出 | $549.0M | — |
| 自由现金流率自由现金流/营收 | 10.5% | — |
| 资本支出强度资本支出/营收 | 2.1% | — |
| 现金转化率经营现金流/净利润 | 1.72× | -0.06× |
| 过去12个月自由现金流最近4个季度 | $2.6B | — |
8季度趋势，按日历期对齐
经营现金流BDXPACS
| Q4 25 | $657.0M | $-3.4M | ||
| Q3 25 | $1.4B | $204.8M | ||
| Q2 25 | $1.2B | $52.6M | ||
| Q1 25 | $164.0M | $150.2M | ||
| Q4 24 | $693.0M | $64.6M | ||
| Q3 24 | $1.2B | $209.2M | ||
| Q2 24 | $1.3B | $34.8M | ||
| Q1 24 | $514.0M | $58.8M |
自由现金流BDXPACS
| Q4 25 | $549.0M | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $35.0M | — | ||
| Q4 24 | $588.0M | — | ||
| Q3 24 | $882.0M | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $380.0M | — |
自由现金流率BDXPACS
| Q4 25 | 10.5% | — | ||
| Q3 25 | 17.0% | — | ||
| Q2 25 | 19.0% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 11.4% | — | ||
| Q3 24 | 16.2% | — | ||
| Q2 24 | 22.4% | — | ||
| Q1 24 | 7.5% | — |
资本支出强度BDXPACS
| Q4 25 | 2.1% | — | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 2.0% | — | ||
| Q3 24 | 5.4% | — | ||
| Q2 24 | 3.6% | — | ||
| Q1 24 | 2.7% | — |
现金转化率BDXPACS
| Q4 25 | 1.72× | -0.06× | ||
| Q3 25 | 2.75× | 3.91× | ||
| Q2 25 | 2.12× | 1.03× | ||
| Q1 25 | 0.53× | 5.28× | ||
| Q4 24 | 2.29× | 33.78× | ||
| Q3 24 | 2.94× | 13.39× | ||
| Q2 24 | 2.66× | — | ||
| Q1 24 | 0.96× | 1.20× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
PACS
暂无分部数据
